[Evaluation of the choroid in central serous chorioretinopathy]
- PMID: 23316655
[Evaluation of the choroid in central serous chorioretinopathy]
Abstract
Studies using indocyanine green angiography (ICGA) revealed that the main cause of central serous chorioretionopathy (CSC) stems from choroidal abnormalities such as choroidal vascular hyperpermeability. However, there are no methods to evaluate the choroid except for either the invasive ICGA or low-resolution ultrasonography. The recently developed enhanced depth imaging optical coherence tomography (EDI-OCT) technique can visualize the choroid appropriately and noninvasively using conventional OCT. EDI-OCT showed that both the affected and unaffected eyes in CSC patients have a thickened choroid; whereas the remarkably thickened choroid in Vogt-Koyanagi-Harada disease decreases immediately after corticosteroid treatment and the eyes with high myopia show a thinner choroid. We evaluated the choroidal thickness after treatment of CSC. The subfoveal choroidal thickness in typical CSC treated with laser photocoagulation showed no changes during the follow-up. On the other hand, the subfoveal choroid in chronic CSC treated with half-dose verteporfin photodynamic therapy (PDT) showed temporary thickening after 2 days but thinned back 1 month after treatment. Both the choroidal thickness and choroidal vascular hyperpermeability in ICGA decreased after PDT, but they did not change after laser photocoagulation. These findings suggest that PDT can affect the abnormal choroid directly and works through a different mechanism from conventional laser photocoagulation. It is important to evaluate the choroid using OCT in CSC and other macular diseases.
Similar articles
-
Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.Ophthalmology. 2010 Sep;117(9):1792-9. doi: 10.1016/j.ophtha.2010.01.023. Epub 2010 May 15. Ophthalmology. 2010. PMID: 20472289
-
Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.Acta Ophthalmol. 2012 Dec;90(8):738-43. doi: 10.1111/j.1755-3768.2011.02157.x. Epub 2011 May 17. Acta Ophthalmol. 2012. PMID: 21586096
-
Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy.Curr Eye Res. 2016;41(1):97-106. doi: 10.3109/02713683.2014.1002047. Epub 2015 Jan 22. Curr Eye Res. 2016. PMID: 25612245
-
[Pathophysiology of macular diseases--morphology and function].Nippon Ganka Gakkai Zasshi. 2011 Mar;115(3):238-74; discussion 275. Nippon Ganka Gakkai Zasshi. 2011. PMID: 21476310 Review. Japanese.
-
Central serous chorioretinopathy and the sclera: what we have learned so far.Jpn J Ophthalmol. 2024 Sep;68(5):419-428. doi: 10.1007/s10384-024-01101-2. Epub 2024 Aug 16. Jpn J Ophthalmol. 2024. PMID: 39150610 Free PMC article. Review.
Cited by
-
Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2155-2161. doi: 10.1007/s00417-019-04426-8. Epub 2019 Jul 31. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 31367848
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources